Closed
Source verified March 4, 2026
Developing Medicines through Open Science (DMOS)
Supports open science drug development partnerships
Latest source updateLast Update: April 18, 2026Latest change: DMOS now clearly includes early to mid-stage clinical projects and a new FAQ/funding tier for TRL 6-7 work.View change
Latest source update
Last Update: April 18, 2026
Latest change: DMOS now clearly includes early to mid-stage clinical projects and a new FAQ/funding tier for TRL 6-7 work.
DMOS scope and funding updated
DMOS scope has expanded to include early to mid-stage clinical projects, not just preclinical work. The FAQ also adds a clinical TRL 6-7 pathway with funding up to $2M and clarifies that open science and IP handling may be considered more flexibly on a case-by-case basis.
Funding available
$ 1,600,000
Deadline
Open continuously
Location
Ontario, Canada
Overview
The Developing Medicines through Open Science (DMOS) program provides up to $2,000,000 per project to support preclinical and clinical drug development in areas of unmet medical need. Eligible projects must involve at least one Canadian SME and align with Conscience’s open science approach.
/100
Opportunity Score
Moderate potential, but conditions must align.
At a glance
Funding available
Financing goals
- Develop strategic partnerships
- Develop a new product or service
- Conduct research and development activities
Eligible Funding
- Maximum amount : 1,600,000 $
- Up to 50% of project cost
Funds Providers
Eligible candidates
Eligible Industries
- All industries
Location
- Ontario
Legal structures
- Non-profit
- Public or Parapublic institution
- For-profit business
Annual revenue
- All revenue ranges
Organisation size
- All organization sizes
Audience
- Canadians
- Startups
Non-profit candidates
Sector of operation
- Higher Education
- Research
- Other Health Services
- Economic, Social and Community Development
Target groups
- Business owners / entrepreneurs
- Nonprofits / charities
- Academia / students
Revenue structures
- All structures
Scope
- National
Next Steps
1
Determine your project
2
Validate your eligibility
Activities funded
- Preclinical and clinical drug development projects addressing unmet medical need.
- Projects to develop drug candidates and establish proof of concept through open science.
- Projects aiming for IND-enabling preclinical studies or human safety and efficacy studies.
Official resources
Program guide
Eligibility
Who is eligible?
- Canadian small and medium-sized enterprises (SMEs)
- Academic research teams
- Organizations involved in preclinical or clinical drug development
Eligible expenses
- Project-related expenses that align with the approved research activities.
- Travel expenses for attending project-progress events requested by the program.
- Salaries and staff hours as tracked in submitted timesheets.
- Other costs incurred with prior formal approval for changes to the research project.
Eligible geographic areas
- Canadian companies
Selection criteria
- Scope fit and unmet medical need.
- Scientific merit and feasibility of the approach.
- Quality of the team and research environment.
- Strength of the drug development plan.
- Alignment with Conscience’s open science policy.
How to apply
- Step 1: Submit a one-page Letter of Intent through the online grants management portal.
- Step 2: Wait for LOI review and feedback.
- Step 3: If selected, submit the full proposal through the online grants management portal.
- Step 4: If funded, sign the grant agreement and attend the virtual onboarding meeting.
Processing and Agreement
- LOIs are reviewed first, and selected applicants are invited to submit a full proposal.
- Proposals are reviewed by a panel of scientific reviewers.
- Applicants may receive feedback and be asked to make changes.
- If approved, applicants must sign the grant agreement within the specified timeframe and attend a virtual onboarding meeting.
Additional information
- Applications may be revised during review.
- Conscience may request additional documents for audit purposes.
- Selected applicants must sign a grant agreement and attend onboarding.
Frequently Asked Questions about the Developing Medicines through Open Science (DMOS) Program
What is the Developing Medicines through Open Science (DMOS)?
The Developing Medicines through Open Science (DMOS) program provides up to $2,000,000 per project to support preclinical and clinical drug development in areas of unmet medical need. Eligible projects must involve at least one Canadian SME and align with Conscience’s open science approach.
How much funding can be received?
Developing Medicines through Open Science (DMOS) Funds up to 50% of admissible expenses, capped at $1,600,000 per project.
Who is eligible for the Developing Medicines through Open Science (DMOS) program?
To be eligible for the Developing Medicines through Open Science (DMOS) program, you must:
Include at least one Canadian SME
Research at TRLs 2-7
Matching funds required
What expenses are eligible under Developing Medicines through Open Science (DMOS)?
Preclinical and clinical drug development projects addressing unmet medical need.
Projects to develop drug candidates and establish proof of concept through open science.
Projects aiming for IND-enabling preclinical studies or human safety and efficacy studies.
Where is the Developing Medicines through Open Science (DMOS) available?
The Developing Medicines through Open Science (DMOS) program is available the province of Ontario.
Is the Developing Medicines through Open Science (DMOS) a grant, loan, or tax credit?
Developing Medicines through Open Science (DMOS) is a Partnering and Collaboration
Who are the financial supporters of the Developing Medicines through Open Science (DMOS)?
Developing Medicines through Open Science (DMOS) is funded by Conscience